abbvie glp-1 receptor agonists weight management diabetes treatments agonist What's New in Obesity Treatment? abbvie glp-1 receptor agonists weight

Food and Drug Administration (FDA) for multiple conditions, including major adverse cardiac events, metabolic-associated steatohepatitis, and sleep apnea, while other conditions are being reviewed

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease

It was the most effective antidiabetic agent anyone had ever seen, says Andrew Young, former vice president of research at Amylin Pharmaceuticals, the San Diegobased company that brought Byetta to market

The vasodilatory effects of GLP-1 RAs can be mediated through GLP-1 receptors or alternative pathways

Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes